In addition, the effectiveness of CD47-targeted therapy in treating solid tumors in clinical trials, particularly in the case of triple-negative breast cancer (TNBC), has been found to be less than satisfactory, suggesting the TNBC cells can escape from phagocytic elimination by macrophages through CD47-independent mechanisms 23, 24. The gene discussed is CD47; the disease is triple-negative breast carcinoma.